640 Memorial Drive
43 articles with Boston Biomedical
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development
Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis
Boston Biomedical, Inc. today announced the first patient has been dosed in a phase 1 study evaluating the investigational agent TP-3654, a PIM kinase inhibitor, in patients with intermediate-2 and high-risk primary or secondary myelofibrosis.
Boston Biomedical, Inc. announced today that its parent company, Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Japan) has invested in the MPM Oncology Innovations Fund (hereinafter, "INV"), and made a donation to the Dana-Farber Innovations Research Fund (hereinafter, "IRF").
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
Boston Biomedical, Inc. announced today that the company has entered into an alliance in oncology research with three world-leading oncology centers of excellence – Columbia University, Harvard University and The Wistar Institute.
Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
Boston Biomedical, Inc. today announced the presentation of new data from a phase 1 study evaluating DSP-7888, an investigational WT1 cancer peptide vaccine, in patients with advanced malignancies.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Boston Biomedical, Inc. announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma will be discontinued due to futility.
Pancreatic cancer is a particularly difficult cancer to treat, and although there have been advances in treatment, it is still an extremely deadly disease. Here’s a look at some recent news concerning pancreatic cancer.
Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis
Boston Biomedical, Inc. announced the continuation of the CanStem303C study evaluating the safety and efficacy of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with advanced colorectal cancer.
According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7.3 percent of cancer deaths.
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
Boston Biomedical, Inc. announced that it will present new research evaluating investigational compound napabucasin in the treatment of multiple cancers, including metastatic pancreatic adenocarcinoma, advanced gastric and gastroesophageal junction adenocarcinoma, and advanced thymoma and thymic carcinoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Boston Biomedical Appoints Edgar Braendle, M.D., Ph.D., as Head of Research and Development and Chief Medical Officer
Boston Biomedical today announced the appointment of Edgar Braendle, M.D., Ph.D., to Executive VP, Head of Research and Development and CMO.
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Brain Cancer
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Myelodysplastic Syndrome
Boston Biomedical Presents Data For Investigational Cancer Stemness Inhibitor Napabucasin In Metastatic Colorectal And Pancreatic Cancer At ESMO GI 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017